trending Market Intelligence /marketintelligence/en/news-insights/trending/MXFWiMydILPAT5ZxJUgjFA2 content esgSubNav
In This List

Amicus prices $225M debt offering

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Amicus prices $225M debt offering

Amicus Therapeutics Inc. priced a $225 million debt offering.

The company will issue unsecured convertible notes due 2023 in a private placement with an option to purchase an additional $25 million worth of the debt.

The notes will bear interest at 3% per annum, with payments due semiannually starting June 15, 2017. They are convertible into company shares at an initial rate of $6.12 per share.

The issue is expected to close Dec. 21 and will help the company refinance a part of its existing debt.

Goldman Sachs & Co., J.P. Morgan Securities LLC, BofA Merrill Lynch and LEERINK Partners are acting as book runners for the offering. Cowen and Co. is acting as lead manager.